Presentation is loading. Please wait.

Presentation is loading. Please wait.

Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the.

Published byMikael Katajakoski Modified over 5 years ago

Similar presentations

Presentation on theme: "Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the."— Presentation transcript:

1 Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung  Luisella Righi, MD, Simona Vatrano, BSc, Federica Di Nicolantonio, PhD, Federica Massa, MD, Giulio Rossi, MD, Alberto Cavazza, MD, Marco Volante, MD, Arianna Votta, MLT, Stefania Izzo, MLT, Marco Lo Iacono, BSc, Francesco Ardissone, MD, Massimo Di Maio, MD, Silvia Novello, MD, Giorgio Vittorio Scagliotti, MD, Mauro Papotti, MD  Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Representative morphological patterns of 54 mucinous adenocarcinoma (ADC) (hematoxylin and eosin stains). (A) Pure invasive mucinous ADC (mucinous features ≥90%); (B) Mixed invasive mucinous ADC with up to 50% nonmucinous ADC component; (C) mucinous ADC with abundant extracellular mucin (≥10% of the tumor); (D) CPA showing mucus pools lined by columnar tumor cells; (E) Mucinous ADC with tuft growth (insert shows high-power field of bunches or small clusters of neoplastic mucinous cells attached to the alveolar wall); (F) Signet ring cells component (cells with large intracellular mucin drops and peripheral nuclei displaced toward one end of the cytoplasm). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Total of genetic variations in 52 mucinous ADC. (A) Total genetic variations identified (namely, nonsense, nonsynonymous likely germinal, nonsynonymous likely somatic, and synonymous alterations) for each sequenced tumor in exonic or regulatory regions. (B) Distribution of nucleotide changes. Syn, synonymous; LG, likely germinal; LS, likely somatic. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Distribution of tumor-specific somatic nonsynonymous mutations. (A) Heatmap of the tumor-specific somatic mutations identified for 52 mucinous ADC samples in each gene clustered according to specific signaling pathways (a sample was considered to harbor a complex mutation when an InDel was detected concomitant with point mutations; RTK, receptor tyrosine kinases). (B) Histogram of the number of sample for each mutated gene. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Kaplan-Meier survival curves for patients segregated according to the number of nonsynonymous likely somatic alterations. Overall survival in tumors with a mutation count of at least 2 (n = 29) compared with tumors with one or no mutations (n = 23) (HR = 0.21, 95% confidence interval: 0.08–0.54, log-rank p < 0.001). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

6 Supplementary Figure 1 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

7 Supplementary Figure 2 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the."

Similar presentations

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung  Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung  Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer  Giuseppe.

Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer  Giuseppe.
Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study  Marco Lo Iacono, PhD, Valentina.

Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study  Marco Lo Iacono, PhD, Valentina.
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma  Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma  Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,
Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study  Massimiliano Paci, MD, Alberto Cavazza, MD, Valerio.

Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study  Massimiliano Paci, MD, Alberto Cavazza, MD, Valerio.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
P63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue  Marco Lo Iacono, PhD, Valentina Monica,

P63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue  Marco Lo Iacono, PhD, Valentina Monica,
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G
Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint.

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint.

Similar presentations

Ads by Google